Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

AHA Scientific Sessions 2021 (Virtual)

13-15 November 2021 (Virtual Meeting)

More insights from ORION

More insights from ORION

News from AHA Scientific Sessions 2021 Baseline glycaemic status or body mass index (BMI) did not impact the efficacy of inclisiran, according to two post hoc analyses of the ORION trials. The first poster presentation reported findings from a post hoc analysis of the ORION-10…

read more »
Long-term evinacumab in homozygous FH

Long-term evinacumab in homozygous FH

News from AHA Scientific Sessions 2021 Evinacumab was the focus of two presentations in patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol). Homozygous FH is a rare genetic lipid disorder, which is characterized by markedly elevated low-density lipoprotein (LDL) cholesterol levels from birth and…

read more »
Combination alirocumab-evinacumab in homozygous FH

Combination alirocumab-evinacumab in homozygous FH

News from AHA Scientific Sessions 2021 Combination treatment with alirocumab plus the angiopoietin-like 3 (ANGPTL3) inhibitor evinacumab, on top of lipid lowering therapy, reduced LDL cholesterol levels by more than 60%, according to a post hoc analysis presented at AHA Scientific Sessions. This report analysed…

read more »
MK-0616: Hope for an oral PCSK9 inhibitor?

MK-0616: Hope for an oral PCSK9 inhibitor?

News from AHA Scientific Sessions 2021 A novel oral PCSK9 inhibitor, MK-0616, showed substantial reduction in LDL cholesterol levels and was generally well tolerated, according to early trial data. Current PCSK9-directed therapies are undoubtedly effective in lowering LDL cholesterol, against a background of statin-ezetimibe therapy….

read more »